More on Mast Therapeutics: Starts Phase II trial for lower-limb ischemia


Mast Therapeutics (MSTX) initiates a Phase II study of MST-188 in patients with acute lower-limb ischemia, which is a complication of peripheral arterial disease that can lead to a limb being amputated and even death. (PR)

Shares are +8.3%.

Q4 Earnings

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs